Antihypertensive activity of lercanidipine and its enantiomers in animal models

Journal of Cardiovascular Pharmacology

Volumn 29, Issue SUPPL. 1, 1997, Pages

  Sironi, G ^a   Colombo, D ^a   Greto, L ^a   Testa, R ^a   Leonardi, A ^a  

^a Recordati SpA   (Italy)

Author keywords

1,4 Dihydropyridine calcium antagonists; Antihypertensive profile in rats and dogs; Hemodynamics; Lercanidipine; Lercanidipine enantiomers

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL; LERCANIDIPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; DIASTOLIC BLOOD PRESSURE; DOG; DOSE CALCULATION; ENANTIOMER; FEMORAL ARTERY FLOW; HEMODYNAMICS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STATISTICAL ANALYSIS; VASODILATATION;

EID: 0030905286     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199729001-00006     Document Type: Article

References (21)

1. Godfraind T. Classification of calcium antagonists. Am J Cordial 1987;59:11B-23B.
2. Triggle DV, Swamy VC. Calcium antagonists: some chemical-pharmacological aspects. Circ Res 1983;52:I17-I28.
3. Saini RK. Calcium antagonists. In: Antonaccio MJ, ed. Cardiovascular pharmacology. New York: Raven Press, 1984:415-52.
4. Kiowski W, Bolli P, Erne P, Buhler FR. Mechanisms of action of calcium antagonists in hypertension. J Cardiovasc Pharmacol 1987;10(suppl 10):S23-8.
5. Eichelbaum M, Echiren M. Clinic pharmacology of calcium antagonists. A clinical review. J Cardiovasc Pharmacol 1984;6: S963-7.
6. Zanchetti A. Role of calcium antagonists in systemic hypertension. Am J Cardiol 1987;59:130B-6B.
7. Omtsuka M, Yokota M, Kodama I, Yamada K. New generation dihydropyridine calcium entry blockers in search of greater selectivity for one tissue subtype. Gen Pharmacol 1989;20:539-56.
8. Freedam D, Waters D. Second generation dihydropyridine calcium antagonists. Drugs 1987;34:578-99.
9. Towart R, Wehinger E, Meyer H, Kazda S. The effect of nimodipine, its optical isomers and metabolites on isolated vascular smooth muscle. Arzneimittelforschung 1982;32:338-46.
10. Takenaka T, Miyazaka I, Asano M, Higuchi S. Vasodilatator and hypotensive effects of the optical isomers of nicardipine (YC-93), a new Ca-antagonist. Jpn J Pharmacol 1982;32:665-70.
11. Brisac A, Champeroux P, Lucet B, Laurent S, Schmitt H. Central and peripheral hypotensive effects of the optical isomers of nicardipine, a dihydropyridine calcium channel antagonist in rats. Eur J Pharmacol 1988;146:171-4.
12. David M, Hofman P, Wegmann E, Zech K. Stereoselectivity in the disposition and metabolism of (+) and (-) niguldipine in dogs [Abstract]. Proc 11th European Workshop on Drug Metabolism, 1988: no. 1.28.
13. Eltze M, Boer R, Sanders K, Ulrich W, Flokerzi D. Prevention of thromboxane-induced coronary vasoconstriction by the enantiomers of the calcium antagonists niguldipine, felodipine, and nitrendipine. Cardiovasc Drugs Ther 1989;3:583.
14. Goldmann S, Soltefuss J. 1-4-Dihydropyridines: effects of chirality and conformation on the calcium antagonists and calcium agonist activities. Angew Chem Int [Ed Eng] 1991;30: 1559-78.
15. Nardi D, Leonardi A, Graziani G, Bianchi G. Asymmetrical diesters of 1,4-dihydropyridine-3,5-dicarboxylic acid. European patent application. 0153016B1, 1985.
16. Birkenhager WH, Reid JL. CAP 4: hemodynamics of experimental hypertension. In: De Jong W, ed. Handbook of hypertension. Vol. IV. Experimental and genetic models of hypertension. Amsterdam: Elsevier, 1984:54-80.
17. Sironi G, Montagna E, Greto L, Bianchi G, Leonardi A, Testa R. Antihypertensive effects of lercanidipine in experimental hypertensive rats and dogs. Arzneimittelforschung 1996;46: 145-52.
18. Sironi G, Montagna E, Greto L, Leonardi A, Testa R. Hemodynamic effects of lercanidipine in anesthetized open-chest dogs. Arzneimittelforschung 1996;46:256-61.
19. Takeyama K, Minato M, Fukuya F, Kawanara S, Mosoki K, Kadokawa T. Antihypertensive activity of alacepril, an orally active angiotensin converting enzyme inhibitor, in renal hypertensive rats and dogs. Arzneimittelforschung 1985;35:1502-7.
20. Burges RA, Dodd MG, Gardiner DG. Pharmacological profile of amlodipine. Am J Cardiol 1989;64:10I-20I.
21. Herbette LG, Vant Erve YMH, Rhodes DG. Interaction of 1,4-dihydropyridine calcium antagonists with biological membranes: lipid bilayer partitioning could occur before drug binding to receptor. J Mol Cell Cardiol 1989;21:187-201.